Date: 2015-12-03
Type of information: Establishment of a new subsidiary in the EU
Compound: chimeric antigen receptor (CAR) T cell therapies
Company: Bluebird bio (USA - MA) ViroMed (South Korea)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: cell therapy/immunotherapy product/gene therapy/CAR T cell therapy
Disease: solid tumors
Details: * On December 3, 2015, bluebird bio and ViroMed announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed’s proprietary humanized antibody to an undisclosed cancer target for solid tumors. Under the terms of the agreement, ViroMed will provide bluebird bio exclusive rights to its novel humanized antibody to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target. bluebird bio will conduct and fund clinical development as well as regulatory and commercial activities. ViroMed’s flagship product, called VM202, has been developed using proprietary vector system and genetically modified HGF gene. VM202 targets 4 indications, all in clinical stage development. VM202-DPN has been approved to initiate Phase 3 study in the US targeting diabetic peripheral neuropathy and VM202-PAD has been approved to initiate Phase 3 study in the US targeting chronic non-healing ulcer in diabetic patients. Phase 1/2 for orphan drug designated VM202-ALS has been completed in the US and VM202-CAD is planned for Phase 2 study in Korea. ViroMed is also running botanical based functional food product and drug development programs.
Financial terms: Financial terms of the agreement include a $1 million upfront payment and subsequent milestone payments to ViroMed, which together could total over $48 million per licensed product if certain development and regulatory milestones are achieved. ViroMed is also eligible to receive tiered royalties on product sales.
Latest news:
